Specialty Drugs Under Risk

Specialty drugs concentrate enormous cost in very few patients. For an organization bearing risk on a modest population, this is the most likely single cause of a bad year, and the correct first response is not clinical.

Why this is a risk problem first

The finance course established that a population must be large enough for the actuarial math to work, and that an organization should not retain risk it cannot absorb. Specialty pharmacy is the sharpest test of both principles.

One member starting a high-cost therapy mid-year can consume a meaningful share of a small population’s entire savings opportunity. That is not a failure of management; it is variance, and no amount of care management prevents a member from developing a condition that requires an expensive drug.

The appropriate responses are the ones the finance and contracting courses covered:

• Stop-loss that explicitly includes pharmacy, since some policies do not.
• Risk corridors that limit total exposure.
• Exclusion or carve-out of specified ultra-high-cost therapies such as gene therapies, negotiated in the contract rather than absorbed silently.
• Risk adjustment that reflects the conditions those drugs treat.

An organization that skips these and tries to manage specialty exposure clinically has accepted a risk it cannot control with tools that cannot control it.

What clinical management can do

With the financing settled, real levers remain:

• Site of care. An infused drug administered in a hospital outpatient department costs substantially more than the same drug in a physician office or at home. The commercial course documented that outpatient facility prices averaged 279 percent of Medicare against 170 percent at ambulatory surgery centers, and the pattern for administered drugs follows the same logic.
• Biosimilar substitution, where a biosimilar exists and is clinically appropriate.
• Appropriate initiation and discontinuation. Ensuring therapy starts for patients who meet criteria and stops when it is not working is both better care and lower cost.
• Waste reduction, including vial sizing and avoiding duplicate therapy.

Notice what is absent from that list: making it harder for eligible patients to get an indicated therapy. That reduces pharmacy spend and is not value.

Worth remembering: the temptation with specialty drugs is to treat every dollar as a target because the dollars are so large. The discipline that prevents harm is to separate three distinct questions. Is this therapy indicated for this patient? That is a clinical question with a clinical answer. Is it being delivered in the least expensive appropriate setting and form? That is a management question with a real answer. Can this organization survive the years when several members need it? That is a financing question, and answering it by restricting the first question is how value-based care earns the reputation its critics give it.

Key takeaways

• Specialty drug cost is concentrated in few members, which makes it a variance problem in small populations.
• Stop-loss including pharmacy, risk corridors, contractual carve-outs, and risk adjustment are the correct first responses.
• Clinical levers are site of care, biosimilar substitution, appropriate initiation and discontinuation, and waste reduction.
• Restricting access for eligible patients reduces spend without producing value.

Sources

• Prices Paid to Hospitals by Private Health Plans: Findings from Round 5.1 of an Employer-Led Transparency Initiative (RAND) (opens in a new tab)
• FTC, Second Interim Staff Report on Prescription Drug Middlemen (January 2025) (opens in a new tab)